Cell membrane coating technology: a promising strategy for biomedical applications
Competition from local distributors creates pricing pressure
A separate retrospective study published in 2025 in JAMA Ophthalmology compared patients who took either oral or subcutaneous semaglutide for type 2 diabetes and matched them to control based on race, sex, A1c and comorbid conditions such as DR, sleep apnea, hypertension and hyperlipidemia
covers core Part A and Part B coinsurance but not the Part A deductible
Though data were collected across multiple post-treatment time points, we caution against using this data to evaluate the pharmacokinetic properties of NLNG, since pharmacokinetic evaluation (e.g., specific details of the time-course of absorption, distribution to tissues besides erythrocytes, and excretion) of NLNG was not a primary goal of this study